The hemoglobin-haptoglobin scavenger receptor (CD163/HbSR) is a monocyte/macrophage-restricted transmembrane protein of the scavenger receptor cysteine-rich family.1 Antigen expression is related to monocyte/macrophage differentiation, with weak expression on peripheral blood monocytes and abundant expression on the majority of tissue macrophages.2-4 To clarify2,3 5whether CD163/HbSR is also expressed on leukemic cells committed to the monocytic lineage, we measured cell-surface expression of CD163/HbSR on leukemic blast cells of 78 patients with acute myeloid leukemia (AML).

AML diagnosis was established by morphology and cytochemistry according to French-American-British (FAB) criteria and immunophenotyping.6 Cases were subclassified as M0 (n = 2), M1 (n = 9), M2, (n = 26), M3 (n = 5), M4 (n = 12), M5 (n = 19), M6 (n = 4), and M7 (n = 1). Density gradient–separated peripheral blood mononuclear cells were stained with fluorescein isothiocyanate (FITC)–labeled anti-CD163 antibody (clone 5C6-FAT; BMA Biomedicals, Augst, Switzerland) or an isotype control antibody (BD Biosciences, Heidelberg, Germany) for measurement of cell-surface CD163/HbSR expression by flow cytometry. Of 47 patients with AML subtypes other than M4 or M5, 41 (87%) had no or only minimal expression of CD163/HbSR (Figure1). In the remaining 6 patients, 5% to 8% of the leukemic blasts stained positively for the antigen when compared with the isotype control antibody. In none of the patients, however, did antigen expression exceed 8%. By comparison, 3 of 12 patients with AML M4 and 16 of 19 patients with AML M5 had CD163/HbSR expression 10% or higher (Figure 1). At the time of initial diagnosis, 2 patients with AML M5 were treated with glucocorticoids, drugs that are known to increase CD163/HbSR expression on normal macrophages;7their effect on antigen expression on malignant cells is, however, unknown.

Fig. 1.

CD163/HbSR expression on mononuclear cells from patients with AML.

Surface expression of CD163/HbSR on blast cells of patients with AML subtypes M0 to M7. None of the patients with AML other than M4 or M5 had CD163 expression higher than 8%. In contrast, 3 of 12 patients with M4 and 16 of 19 patients with M5 had CD163/HbSR expression 10% or higher.

Fig. 1.

CD163/HbSR expression on mononuclear cells from patients with AML.

Surface expression of CD163/HbSR on blast cells of patients with AML subtypes M0 to M7. None of the patients with AML other than M4 or M5 had CD163 expression higher than 8%. In contrast, 3 of 12 patients with M4 and 16 of 19 patients with M5 had CD163/HbSR expression 10% or higher.

Close modal

In line with this lineage-restricted antigen expression, we observed strong correlations between CD163/HbSR and other markers predominantly found in monocytic leukemia,8,9 such as CD14, CD64, and lysozyme (Table1). Weaker correlations were found between CD163/HbSR and the myeloid markers CD15, CD33, CDw65, the percentage of unspecific esterase-positive blast cells, and transcobalamin II10(Table 1), but not for CD13 and CD117 (not shown). In addition, weak inverse correlations were found between CD163/HbSR expression and positivity of cytochemical staining for peroxidase and chloroacetate esterase and flow cytometric detection of intracellular myeloperoxidase (not shown), markers which are usually not expressed by monocytic leukemias.6 A weak correlation was also found for CD163/HbSR and blood levels of C-reactive protein, possibly reflecting the acute-phase regulated expression of CD163/HbSR.

In conclusion, these results confirm early studies2 3 and demonstrate that CD163/HbSR is expressed not only on mature monocytes and macrophages but also on leukemic cells. We found the antigen exclusively on the majority of monocytic and a significant subset of myelomonocytic leukemias, suggesting that the restriction of CD163/HbSR expression to cells committed to the monocytic lineage is preserved beyond malignant transformation; this lineage-restricted pattern of antigen expression may thus be useful for the immunophenotypic subclassification of leukemias.

1
Kristiansen
M
Graversen
JH
Jacobsen
C
et al
Identification of the haemoglobin scavenger receptor.
Nature.
409
2001
198
201
2
Radzun
HJ
Kreipe
H
Bödewadt
S
Hansmann
M-L
Barth
J
Parwaresch
MR
Ki-M8 monoclonal antibody reactive with an intracytoplasmic antigen of monocyte/macrophage lineage.
Blood.
69
1987
1320
1327
3
Backé
E
Schwarting
R
Gerdes
J
Ernst
M
Stein
H
Ber-MAC3: new monoclonal antibody that defines human monocyte/macrophage differentiation antigen.
J Clin Pathol.
44
1991
936
945
4
Pulford
K
Micklem
K
McCarthy
S
Cordell
J
Jones
M
Mason
DY
A monocyte/macrophage antigen recognized by the four antibodies GHI/61, Ber-MAC3, Ki-M8 and SM4.
Immunology.
75
1992
588
595
5
Pulford
K
Micklem
K
Law
SKA
Mason
DY
CD163 (M130 antigen) workshop panel report.
Leukocyte typing VI: white cell differentiation antigens.
Kishimoto
T
Kikutani
H
von dem Borne
AEGK
et al
1997
1089
1091
Garland Publishing
New York, NY
6
Kinney
MC
Lukens
JN
Classification and differentiation of the acute leukemias.
Wintrobe's Clinical Hematology
10th edition.
Lee
GR
Foerster
J
Lukens
J
Paraskevas
F
Greer
JP
Rodgers
GM
1998
2209
2240
Williams & Wilkins
Baltimore, MD
7
Schaer
DJ
Boretti
FS
Schoedon
G
Schaffner
A
Induction of the CD163-dependent haemoglobin uptake by macrophages as a novel anti-inflammatory action of glucocorticoids.
Br J Haematol.
119
2002
239
243
8
Greer
JP
Baer
MR
Kinney
MC
Acute myelogenous leukemia.
Wintrobe's Clinical Hematology
10th edition.
Lee
GR
Foerster
J
Lukens
J
Paraskevas
F
Greer
JP
Rodgers
GM
1998
2272
2319
Williams & Wilkins
Baltimore, MD
9
Ball
ED
McDermott
J
Griffin
JD
Davey
FR
Davis
R
Bloomfield
CD
Expression of the three myeloid cell-associated immunoglobulin G Fc receptors defined by murine monoclonal antibodies on normal bone marrow and acute leukemia cells.
Blood.
73
1989
1951
1956
10
Fehr
J
De Vecchi
P
Transcobalamin II: a marker for macrophage/histiocyte proliferation.
Am J Clin Pathol.
84
1985
291
296
Sign in via your Institution